Medicare beneficiaries do not pay coinsurance for CRC screenings. However, if the gastroenterologist identifies a polyp for removal, the screening becomes a diagnostic test, which does include coinsurance.
The proposed 2022 Physician Fee Schedule, issued July 13, gradually would reduce the percentage of coinsurance when CRC screenings become diagnostic tests over the next decade. Beneficiaries would be responsible for 20 percent in 2022, 15 percent in 2023 to 2026, and 10 percent in 2027 to 2029.
By 2030, coinsurance would be eliminated for Medicare beneficiaries who undergo a CRC screening that becomes a diagnostic test.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
